Abstract
Background: Peptic ulcer disease had a tremendous effect on morbidity and mortality until the last decades of the 20th century when epidemiological trends started to point to an impressive fall in its incidence. The present study to assess the prevalence of Helicobacter Pylori (HP) infection in patients undergoing emergency surgery for repair of complications of peptic ulcer.
Material & Methods: A prospective hospital based study in Dept. of Surgery, S.P.Medical College and P.B.M Hospital, Bikaner, All patients undergoing emergency surgeries within study duration and fulfilling eligibility criteria were included in the study. All patients underwent surgery. Biopsy was taken during operation for HP nearly surgical area. Evaluation of cytology results was based on the following criteria. We subdivided the results of 50 cytology specimens in 3 categories: material unsatisfactory for interpretation, negative results and positive results
Results: In this study a total 50 cases of perforated peptic ulcer were identified during study period. Out of 50 cases 35 (70%) were males and 15 (30%) were females (table 1) with mean age 45.8± 10.76 (table 2). The most common symptoms clinically were epigastric / upper abdominal pain 30(60%), heartburn 25 (50%), nausea / vomiting 28(56%) and constipation 25 (50%). The precipitating factors like use of NSAIDS, cigerrett smoking, and alcoholism were found in 50%, 38%, and 10% respectively.
Conclusion: Most of the times there are no alarming signs before actual ailment, but seeking proper medical help in time results in favourable results. They should be advised to avoid the common risk factors like too much spicy food, smoking, excess alcohol use, and indiscriminate use of NSAIDs and should seek proper medical advice in time.
Key Words: Helicobacter pylori, NSAIDs, Perforated Peptic ulcer, Laprotomy.
References
1. Najm, WI (September 2011). "Peptic ulcer disease.". Primary care. 38 (3): 383–94.
2. "Definition and Facts for Peptic Ulcer Disease". National Institute of Diabetes and Digestive and Kidney Diseases. Retrieved 28 February 2015.
3. Rao, S. Devaji (2014). Clinical Manual of Surgery. Elsevier Health Sciences. p. 526.
4. Milosavljevic, T; Kostić-Milosavljević, M; Jovanović, I; Krstić, M (2011). "Complica-tions of peptic ulcer disease.". Digestive diseases (Basel, Switzerland).29(5):491–3.
5. Global Burden of Disease Study 2013, Collaborators (22 August 2015). "Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013.". Lancet (London, England). 386 (9995): 743–800.
6. Snowden FM (October 2008). "Emerging and reemerging diseases: a historical perspective". Immunol. Rev.225 (1):9–26.
7. GBD 2013 Mortality and Causes of Death, Collaborators (17 December 2014). "Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013.". Lancet. 385: 117–71.
8. Wang, AY; Peura, DA (October 2011). "The prevalence and incidence of Helicobacter pylori-associated peptic ulcer disease and upper gastrointestinal bleeding throughout the world.". Gastrointestinal endoscopy clinics of North America. 21 (4): 613–35.
9. The Nobel Prize in Physiology or Medicine 2005". nobelprize.org. Nobel Media AB. Retrieved 3 June2015.
10. Cullen DJ; Hawkey GM; Greenwood DC; et al. (1997). "Peptic ulcer bleeding in the elderly: relative roles of Helicobacter pylori and non-steroidal anti-inflammatory drugs". Gut. 41 (4): 459–62.
11. "Peptic Ulcer". Home Health Handbook for Patients & Caregivers. Merck Manuals. October 2006.
12. Brown LM (2000). "Helicobacter pylori: epidemiology and routes of transmission.". Epidemiol. Rev. 22(2): 283–97.
13. Oladejo O. Lawal, Rotimi O, Okeke I. Helicobacter Pylori in Gastroduodenal Diseases. Journal of the National Medical Association 2007;99(1):31-4.
14. Kaffes A, Cullen J, Mitchell H, Katelaris PH. Effect of Helicobacter Pylori Infection and Low-Dose Aspirin Use on Iron Stores in the Elderly 2003. Gastroenterol Hepatol 18(9):1024-8.
15. Bjorkman J. H. pylori, NSAIDs, and Peptic Ulcer Bleeding 2005. Clin Gastroenterol Hepatol;3:859-64.
16. Oliveira AG, Santos A, Guerra GB, Rocha GA, Rocha AM, Oliveira CA, et al. babA2- and cagAPositive Helicobacter pylori Strains Are Associated with Duodenal Ulcer and Gastric Carcinoma in Brazil. Journal of Clinical Microbiology 2003; 41 (8): 3964-6.
17. Bjorkman DJ. NSAIDs and H. pylori: A Dangerous Combination?. Lancet 2002; 359:3-4.
18. Graham DY. NSAIDs, Helicobacter pylori, and Pandora's Box. The New England Journal of Medicine 2002;347 (26):2162-4.
19. Aguemon BD, Struelens MJ, Massoug-bodji A, Ouendo EM. Prevalence and risk-factors for Helicobacter pylori infection in urban and rural Beninese populations. Clinical microbiology and infection 2005;11(8):611-7.
20. Bueno FS, Marín P, Ríos A, Aguayo JL, Robles R, Pinero A, et al. Has the Incidence of Perforated Peptic Ulcer Decreased over the Last Decade? / with Invited Commentary. Dig Surg 2001; 18:444-8.
21. Svanes C. Trends in perforated peptic ulcer: incidence, etiology, treatment, and prognosis. World J Surg 2000;24(3):277-83.
22. Essa F, Taj Y, Kazmi SU, Abdullah E. Sensitivity and Specificity of various diagnostic tests in the detection of Helicobacter Pylori. J Coll Physicians Surg Pak 2003;13(2):90-3.
23. Gisbert JP, Legido J, Sanz IG, Pajares M. Helicobacter pylori and perforated peptic ulcer. Prevalence of the infection and role of non-steroidal anti -inflammatory drugs. Digestive and Liver Disease 2004;36(2): 116-20.
DOI: https://dx.doi.org/10.18535/jmscr/v5i4.225
